Allergan and Heptares Announce Alzheimer’s Disease Treatment R&D and Commercialization Partnership

Allergan and Heptares Announce Alzheimer’s Disease Treatment R&D and Commercialization Partnership
Dublin, Ireland-based global pharmaceutical company Allergan and Heptares Therapeutics, a clinical-stage pharmaceutical company whose proprietary technologies have created new medicines with the potential to transform Alzheimer’s disease, have entered into a global research and development and commercialization partnership for the treatment of Alzheimer’s disease (AD) and other neurological disorders. With the partnership, Allergan will license exclusive

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *